Corvus Pharmaceuticals, Inc. (CRVS) Operating Margin
- Operating margin · 12 months: Value (m); Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | (m) | Operating income / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -56.96M USD | Operating Income (Loss) |
| Revenue | (m) | |
| Cost of products and services | (m) | |
| Research and development | 45.53M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-56.96M | (m) | (m) | $45.53M | (m) | (m) |
| 2026-03-31 | $-47.93M | (m) | (m) | $37.44M | (m) | (m) |
| 2025-12-31 | $-42.97M | (m) | (m) | $33.72M | (m) | (m) |
| 2025-09-30 | $-38.86M | (m) | (m) | $29.75M | (m) | (m) |
| 2025-06-30 | $-35.54M | (m) | (m) | $26.52M | (m) | (m) |
| 2025-03-31 | $-31.22M | (m) | (m) | $22.76M | (m) | (m) |
| 2024-12-31 | $-27.55M | (m) | (m) | $19.39M | (m) | (m) |
| 2024-09-30 | $-25.09M | (m) | (m) | $17.41M | (m) | (m) |
| 2024-06-30 | $-23.40M | (m) | (m) | $16.15M | (m) | (m) |
| 2024-03-31 | $-23.09M | (m) | (m) | $16.01M | (m) | (m) |
| 2023-12-31 | $-23.41M | (m) | (m) | $16.53M | (m) | (m) |
| 2023-09-30 | $-23.42M | (m) | (m) | $16.61M | (m) | (m) |
| 2023-06-30 | $-30.34M | (m) | (m) | $23.01M | (m) | (m) |
| 2023-03-31 | $-31.73M | (m) | (m) | $23.96M | (m) | (m) |
| 2022-12-31 | $-32.56M | (m) | (m) | $24.47M | (m) | (m) |
| 2022-09-30 | $-33.71M | (m) | (m) | $25.18M | (m) | (m) |
| 2022-06-30 | $-30.28M | (m) | (m) | $21.80M | (m) | (m) |
| 2022-03-31 | $-34.56M | (m) | (m) | $25.98M | (m) | (m) |
| 2021-12-31 | $-38.63M | (m) | (m) | $29.11M | (m) | (m) |
| 2021-09-30 | $-41.70M | (m) | (m) | $31.52M | (m) | (m) |
| 2021-06-30 | $-42.50M | (m) | (m) | $31.15M | (m) | (m) |
| 2021-03-31 | $-41.97M | (m) | (m) | $29.90M | (m) | (m) |
| 2020-12-31 | $-43.76M | (m) | (m) | $31.83M | (m) | (m) |
| 2020-09-30 | $-45.32M | (m) | (m) | $33.56M | (m) | (m) |
| 2020-06-30 | $-46.99M | (m) | (m) | $35.94M | (m) | (m) |
| 2020-03-31 | $-49.82M | (m) | (m) | $38.72M | (m) | (m) |
| 2019-12-31 | $-48.85M | (m) | (m) | $37.98M | (m) | (m) |
| 2019-09-30 | $-48.59M | (m) | (m) | $37.45M | (m) | (m) |
| 2019-06-30 | $-48.22M | (m) | (m) | $36.83M | (m) | (m) |
| 2019-03-31 | $-46.88M | (m) | (m) | $35.90M | (m) | (m) |
| 2018-12-31 | $-49.22M | (m) | (m) | $38.59M | (m) | (m) |
| 2018-09-30 | $-50.24M | (m) | (m) | $39.88M | (m) | (m) |
| 2018-06-30 | $-52.03M | (m) | (m) | $42.24M | (m) | (m) |
| 2018-03-31 | $-54.95M | (m) | (m) | $44.91M | (m) | (m) |
| 2017-12-31 | $-56.52M | (m) | (m) | $46.30M | (m) | (m) |
| 2017-09-30 | $-55.59M | (m) | (m) | $45.75M | (m) | (m) |
| 2017-06-30 | $-53.12M | (m) | (m) | $42.72M | (m) | (m) |
| 2017-03-31 | $-46.77M | (m) | (m) | $37.46M | (m) | (m) |
| 2016-12-31 | $-36.98M | (m) | (m) | $29.36M | (m) | (m) |
| 2016-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | $-13.77M | (m) | (m) | $11.35M | (m) | (m) |
| 2015-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Apnimed, Inc. (APMD) | United States | $0.899B |